Pedaling away chemo pain: cycling study offers hope

NCT ID NCT07150117

First seen Sep 30, 2025 · Last updated Jun 19, 2026 · Updated 42 times

Summary

This study tests if a supervised cycling program can reduce nerve pain caused by chemotherapy. Thirty adults with cancer will ride a stationary bike twice a week for 12 weeks. Researchers will check if the exercise is safe, enjoyable, and helps with symptoms and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cross Cancer Institute

    RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

supervised cycling-based aerobic exercise

What this could lead to

If this works, it could point toward a simple, drug-free way to manage nerve pain from chemotherapy.

What could go wrong

This is a very small, early proof-of-concept study, not a large trial. It may not show clear benefits, and results may not apply to everyone with nerve pain.

Conditions

The condition(s) this trial relates to.

cancer chemotherapy-induced neuropathy Motor Activity neoplasm peripheral nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.